Gary Titus compensation by year
UroGen Pharma Summary Compensation Table · all 3 fiscal years held| Component | FY2016 | FY2017 | FY2018 |
|---|---|---|---|
| Salary | $314,053 | $304,167 | $175,000 |
| Bonus | $0 | $25,000 | $0 |
| Stock awards | $0 | $0 | $0 |
| Option awards | $87,847 | $622,224 | $695,835 |
| Non-equity incentive | $0 | $125,125 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 |
| All other | $452 | $1,161 | $2,616,274 |
| Total | $402,353 | $1,077,677 | $3,487,109 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: UroGen Pharma Ltd. DEF 14A filed April 26, 2019, accession 0001193125-19-122589, and prior-year filings.
How this page was built: the UroGen Pharma Ltd. filed document, accession 0001193125-19-122589. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2019.
UroGen Pharma’s named executive officers, FY2018
as the company reported each| Named executive officer | Role | FY2018 total |
|---|---|---|
| Ron Bentsur | Former Chief Executive Officer (7) | $5,950,112 |
| Stephen Mullennix | Chief Operating Officer (9) | $4,309,568 |
| Gil Hakim | Former President (8) | $3,856,219 |
| Gary Titus · this page | Former Chief Financial Officer (11) | $3,487,109 |
| Peter Pfreundschuh | Chief Financial Officer (8) | $2,485,800 |
| Mark Schoenberg | Chief Medical Officer (10) | $300,000 |
The full UroGen Pharma compensation record
free company briefThis page is one person within UroGen Pharma's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the UroGen Pharma proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are UroGen Pharma's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.